This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Original) Compounds of the formula I



I

in which

X-Y-D-E denotes CH=CH-CH=CH, N=CH-CH=CH, CH=N-CH=CH, CH=CH-N=CH, CH=CH-CH=N, N=CH-N=CH, CH=N-CH=N, $N^+(-O^-)$=CH-CH=CH, CH=$N^+(-O^-)$-CH=CH, CH=CH-$N^+(-O^-)$=CH, CH=CH-CH=$N^+(-O^-)$, NH-CO-CH=CH, CH=CH-CO-NH, CO-NH-CH=CH, CH=CH-NH-CO,

in which the H atoms of the -CH- groups may be substituted by Hal, A, OH, OA, A-COO-, Ph-$(CH_2)_n$-COO-, cycloalkyl-$(CH_2)_n$-COO-, A-CONH-, A-CONA-, Ph-CONA-, N_3, NH_2, NO_2, CN, COOH, COOA, $CONH_2$, CONHA, $CON(A)_2$, O-allyl, O-propargyl and/or O-benzyl,

Ph denotes phenyl which is unsubstituted or mono-, di- or trisubstituted by A, OA, OH or Hal,

R^1 denotes Hal, -C≡C-H, -C≡C-A, OH or OA,

R^2 denotes H, Hal or A,

R^3 denotes 2-oxo-1*H*-pyridin-1-yl, 2-oxo-1*H*-pyrazin-1-yl, 2-oxopiperidin-1-yl, 2-oxo-pyrrolidin-1-yl, 2-oxo-1,3-oxazinan-3-yl, 3-oxomorpholin-4-yl, 2-oxotetrahydropyrimidin-1-yl, 3-oxo-2*H*-pyridazin-2-yl, 4-oxo-1*H*-pyridin-1-yl, 2-oxoimidazolidin-1-yl, 2,6-dioxo-piperidin1-yl, 2-oxopiperazin-1-yl, 2,6-dioxopiperazin-1-yl, 2,5-dioxopyrrolidin-1-yl, 2-oxo-1,3-oxazolidin-3-yl, 2-caprolactam-1-yl (= 2-oxoazepan-1-yl), 2-azabicyclo[2.2.2]-octan-3-on-2-yl, 5,6-dihydro-1*H*-pyrimidin-2-oxo-1-yl, 4*H*-1,4-oxazin-4-yl, 2-iminopiperidin-1-yl,

2-iminopyrrolidin-1-yl, 3-iminomorpholin-4-yl, 2-iminoimidazolidin-1-yl or 2-imino-1*H*-pyrazin-1-yl, each of which is unsubstituted or mono- or disubstituted by A, OH and/or OA,

A denotes unbranched, branched or cyclic alkyl having 1-10 C atoms, in which, in addition, 1-7 H atoms may be replaced by F and/or chlorine,

Hal denotes F, Cl, Br or I,

N denotes 0, 1, 2 or 3,

and pharmaceutically usable derivatives, solvates, salts and stereoisomers thereof, including mixtures thereof in all ratios.

2. (Original) Compounds according to Claim 1 in which

R^1 denotes Hal or -C≡C-H,

and pharmaceutically usable derivatives, solvates, salts and stereoisomers thereof, including mixtures thereof in all ratios.

3. Compounds according to Claim 1 or 2 in which

R^1 denotes Hal,

and pharmaceutically usable derivatives, solvates, salts and stereoisomers thereof, including mixtures thereof in all ratios.

4. (Currently Amended) Compounds according to ~~one or more of Claims 1-3~~ Claim 1 in which

X-Y-D-E denotes CH=CH-CH=CH, N=CH-CH=CH, CH=N-CH=CH, CH=CH-N=CH, CH=CH-CH=N, N=CH-N=CH, CH=N-CH=N, $N^+(-O^-)$=CH-CH=CH, CH=$N^+(-O^-)$-CH=CH, CH=CH-$N^+(-O^-)$=CH, CH=CH-CH=$N^+(-O^-)$, NH-CO-CH=CH, CH=CH-CO-NH, CO-NH-CH=CH or CH=CH-NH-CO,

in which the H atoms of the -CH- groups may be substituted by Hal, A, OH and/or OA,

and pharmaceutically usable derivatives, solvates, salts and stereoisomers thereof, including mixtures thereof in all ratios.

5. (Currently Amended) Compounds according to ~~one or more of Claims 1-4~~ Claim 1

in which X-Y-D-E denote CH=CH-CH=CH, N=CH-CH=CH, CH=N-CH=CH, CH=CH-N=CH, CH=CH-CH=N, N=CH-N=CH, CH=N-CH=N, $N^+(-O^-)$=CH-CH=CH, CH=$N^+(-O^-)$-CH=CH, CH=CH-$N^+(-O^-)$=CH or CH=CH-CH=$N^+(-O^-)$,
in which the H atoms of the -CH- groups may be substituted by Hal, OH and/or OA,
and pharmaceutically usable derivatives, solvates, salts and stereoisomers thereof, including mixtures thereof in all ratios.

6. (Currently Amended) Compounds according to ~~one or more of Claims 1-5~~ Claim 1 in which
R^3 denotes 2-oxo-1*H*-pyridin-1-yl, 2-oxo-1*H*-pyrazin-1-yl, 2-oxopiperidin-1-yl, 2-oxo-pyrrolidin-1-yl, 2-oxo-1,3oxazinan-3-yl, 3-oxomorpholin-4-yl, 2-oxotetrahydropyrimidin-1-yl, 3-oxo-2*H*-pyridazin-2-yl, 4-oxo-1*H*-pyridin-1-yl, 2-oxoimidazolidin-1-yl or 2-oxo-piperazin-1-yl, and pharmaceutically usable derivatives, solvates, salts and stereoisomers thereof, including mixtures thereof in all ratios.

7. (Currently Amended) Compounds according to ~~one or more of Claims 1-6~~ Claim 1 in which
R^3 denotes 2-oxo-1*H*-pyridin-1-yl or 3-oxomorpholin-4-yl,
and pharmaceutically usable derivatives, solvates, salts and stereoisomers thereof, including mixtures thereof in all ratios.

8. (Currently Amended) Compounds according to ~~one or more of Claims 1-7~~ Claim 1 in which
X-Y-D-E denotes CH=CH-CH=CH, N=CH-CH=CH, CH=N-CH=CH, CH=CH-N=CH, CH=CH-CH=N, N=CH-N=CH, CH=N-CH=N, $N^+(-O^-)$=CH-CH=CH, CH=$N^+(-O^-)$-CH=CH, CH=CH-$N^+(-O^-)$=CH or CH=CH-CH=$N^+(-O^-)$,
in which the H atoms of the -CH- groups may be substituted by Hal, OH and/or OA,
R^1 denotes Hal,
R^2 denotes H, Hal or A,
R^3 denotes 2-oxo-1*H*-pyridin-1-yl, 2-oxo-1*H*-pyrazin-1-yl, 2-oxopiperidin-1-yl, 2-oxo-pyrrolidin-1-yl, 2-oxo-1,3-oxazinan-3-yl, 3-oxomorpholin-4-yl, 2-oxotetrahydropyrimidin-1-

yl, 3-oxo-2*H*-pyridazin-2-yl, 4-oxo-1*H*-pyridin-1-yl, 2-oxoimidazolidin-1-yl or 2-oxo-piperazin-1-yl,

A denotes unbranched, branched or cyclic alkyl having 1-10 C atoms, in which, in addition, 1-7 H atoms may be replaced by F and/or chlorine,

Hal denotes F, Cl, Br or I,

and pharmaceutically usable derivatives, solvates, salts and stereoisomers thereof, including mixtures thereof in all ratios.

9. (Original) Compounds according to Claim 1 selected from the group

1-(4-chlorophenyl)-3-(4-hydroxy-2-{3-[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]ureido}phenyl)urea,

1-(4-chlorophenyl)-3-(4-{3-[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]-ureido}pyridin-3-yl)urea,

1-(4-chlorophenyl)-3-(4-{3-[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]-ureido}-1-oxypyridin-3-yl)urea,

1-(2-chloro-4-{3-[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]ureido}-pyridin-3-yl)-3-(4-chlorophenyl)urea,

1-(2-chloro-4-{3-[3-chloro-4-(3-oxomorpholin-4-yl)phenyl]ureido}-pyridin-3-yl)-3-(4-chlorophenyl)urea,

1-(4-chlorophenyl)-3-(4-hydroxy-2-{3-[4-(2-oxo-2*H*-pyridin-1-yl)-phenyl]ureido}phenyl)urea,

1-(4-chlorophenyl)-3-(3-{3-[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]-ureido}pyridin-2-yl)urea,

1-(4-chlorophenyl)-3-(3-{3-[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]-ureido}-1-oxypyridin-4-yl)urea,

1-(4-chlorophenyl)-3-(5-hydroxy-2-{3-[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]ureido}phenyl)urea,

1-(4-chlorophenyl)-3-(4-hydroxy-2-{3-[2-fluoro-4-(3-oxomorpholin-4-yl)phenyl]ureido}phenyl)urea,

1-(4-chlorophenyl)-3-(4-hydroxy-2-{3-[2-methyl-4-(3-oxomorpholin-4-yl)phenyl]ureido}phenyl)urea,

1-(4-chlorophenyl)-3-(3-{3-[2-fluoro-4-(3-oxomorpholin-4-yl)phenyl]-ureido}-1-oxypyridin-4-yl)urea,

1-(4-chlorophenyl)-3-(3-{3-[2-methyl-4-(3-oxomorpholin-4-yl)phenyl]-ureido}-1-oxypyridin-4-yl)urea,

and pharmaceutically usable derivatives, solvates, salts and stereoisomers thereof, including mixtures thereof in all ratios.

10. (Currently Amended) Process for the preparation of compounds of the formula I according to ~~Claims 1-9~~ Claim 1 and pharmaceutically usable derivatives, solvates, salts and stereoisomers thereof, characterised in that

a) a compound of the formula II



II

in which X-Y-D-E and R^1 have the meanings indicated in Claim 1,
is reacted with a chloroformate derivative to give an intermediate carbamate derivative,

which is subsequently reacted with a compound of the formula III



III

in which

R^2 and R^3 have the meanings indicated in Claim 1,

or

b) a compound of the formula IV



IV

in which X-Y-D-E, R^2 and R^3 have the meanings indicated in Claim 1,

is reacted with a compound of the formula V



V

in which R^1 has the meaning indicated in Claim 1,

or

c) a radical X-Y-D-E is converted into another radical X-Y-D-E by oxidising the radical X-Y-D-E,
and/or a base or acid of the formula I is converted into one of its salts.

11. (Currently Amended) Compounds of the formula I according to ~~one or more of Claims 1 to 9~~ Claim 1 as inhibitors of coagulation factor Xa.

12. (Currently Amended) Compounds of the formula I according to ~~one or more of Claims 1 to 9~~ Claim 1 as inhibitors of coagulation factor VIIa.

13. (Currently Amended) Medicaments comprising at least one compound of the formula I according to ~~one or more of Claims 1 to 9~~ Claim 1 and/or pharmaceutically usable derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios, and optionally excipients and/or adjuvants.

14. (Currently Amended) Medicaments comprising at least one compound of the formula I according to ~~one or more of Claims 1 to 9~~ Claim 1 and/or pharmaceutically usable derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios, and at least one further medicament active ingredient.

15. (Currently Amended) Use of compounds according to ~~one or more of Claims 1 to 9~~ Claim 1 and/or physiologically acceptable salts and solvates thereof for the preparation of a medicament for the treatment of thromboses, myocardial infarction, arteriosclerosis, inflammation, apoplexy, angina pectoris, restenosis after angioplasty, claudicatio intermittens, migraine, tumours, tumour diseases and/or tumour metastases.

16. (Currently Amended) Set (kit) consisting of separate packs of

(a) an effective amount of a compound of the formula I according to ~~one or more of Claims 1 to 9~~ Claim 1 and/or pharmaceutically usable derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios,

and

(b) an effective amount of a further medicament active ingredient.

17. (Currently Amended) Use of compounds of the formula I according to ~~one or more of Claims 1 to 9~~ Claim 1 and/or pharmaceutically usable derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios,
for the preparation of a medicament for the treatment of thromboses, myocardial infarction,

arteriosclerosis, inflammation, apoplexy, angina pectoris, restenosis after angioplasty, claudicatio intermittens, migraine, tumours, tumour diseases and/or tumour metastases, in combination with at least one further medicament active ingredient.

18. (Original) Intermediate compounds of the formula II-1



II-1

in which

X-Y-D-E denotes CH=CH-CH=CH, N=CH-CH=CH, CH=N-CH=CH, CH=CH-N=CH, CH=CH-CH=N, N=CH-N=CH, CH=N-CH=N, NH-CO-CH=CH, CH=CH-CO-NH, CO-NH-CH=CH, CH=CH-NH-CO,

in which the H atoms of the -CH- groups may be substituted by Hal, A, OH, OA, A-COO-, Ph-$(CH_2)_n$-COO-, cycloalkyl-$(CH_2)_n$-COO-, A-CONH-, A-CONA-, Ph-CONA-, N_3, NH_2, NO_2, CN, COOH, COOA, $CONH_2$, CONHA, $CON(A)_2$, O-allyl, O-propargyl and/or O-benzyl,

Ph denotes phenyl which is unsubstituted or mono-, di- or trisubstituted by A, OA, OH or Hal,

R^1 denotes Hal, -C≡C-H, -C≡C-A, OH or OA,

A denotes unbranched, branched or cyclic alkyl having 1-10 C atoms, in which, in addition, 1-7 H atoms may be replaced by F and/or chlorine,

Hal denotes F, Cl, Br or I,

n denotes 0, 1, 2 or 3,

and salts thereof.

19. (Original) Intermediate compounds according to Claim 18 in which

X-Y-D-E denotes CH=CH-CH=CH, N=CH-CH=CH, CH=N-CH=CH, CH=CH-N=CH,

CH=CH-CH=N, N=CH-N=CH, CH=N-CH=N,

in which the H atoms of the -CH- groups may be substituted by Hal, OH and/or OA,

R^1 denotes Hal,

A denotes unbranched, branched or cyclic alkyl having 1-10 C atoms, in which, in addition, 1-7 H atoms may be replaced by F and/or chlorine,

Hal denotes F, Cl, Br or I,

and salts thereof.